Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial-Reference-Cited by-同舟云学术

Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial

Published:2023-07 Issue: Volume: Page:
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Djaïleb Loïc,Armstrong Wesley R.,Thompson Daniel,Gafita Andrei,Farolfi Andrea,Rajagopal Abhejit,Grogan Tristan R.,Nguyen Kathleen,Benz Matthias R.,Hotta Masatoshi,Barbato Francesco,Ceci Francesco,Schwarzenböck Sarah M.,Unterrainer Marcus,Zacho Helle D.,Juarez Roxanna,Cooperberg Matthew,Carroll Peter,Washington Samuel,Reiter Robert E.,Eiber Matthias,Herrmann Ken,Fendler Wolfgang P.,Czernin Johannes,Hope Thomas A.,Calais Jeremie

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent;Mottet;Eur Urol,2021

2. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer;Han;J Urol,2003

3. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy;Ward;J Urol,2003

4. Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy;Liesenfeld;J Urol,2017

5. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy;Freedland;JAMA,2005

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study;The Lancet Oncology;2024-09

2. Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol 2024;86:52–60;European Urology;2024-08

3. [ ⁶⁸ Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer;Expert Review of Molecular Diagnostics;2024-07-02

4. Prostate-specific Membrane Antigen;PET Clinics;2024-07

5. A Prospective Randomized Multicenter Study on the Impact of [¹⁸F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer;Journal of Nuclear Medicine;2024-06-06